Injection, oritavancin 10 mg
Products billed under this code include Kimyrsa.
Payment limit per 10 MG, by effective quarter, 2Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Kimyrsa.
Payment limit per 10 MG, by effective quarter, 2Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Kimyrsa | Melinta Therapeutics, LLC | 70842-0225-01 | 120 | $5,327.04 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $44.392 | −$3.017 | 10 MG | Injection, oritavancin 10 mg | v1, posted September 17, 2026 |
| 3Q26 | $47.409 | +$3.69 | 10 MG | Injection, oritavancin 10 mg | v1, posted September 15, 2026 |
| 2Q26 | $43.719 | +$0.66 | 10 MG | Injection, oritavancin 10 mg | v1, posted September 15, 2026 |
| 1Q26 | $43.059 | +$0.581 | 10 MG | Injection, oritavancin 10 mg | v1, posted September 15, 2026 |
| 4Q25 | $42.478 | +$1.074 | 10 MG | Injection, oritavancin 10 mg | v1, posted September 8, 2026 |
| 3Q25 | $41.404 | −$1.361 | 10 MG | Injection, oritavancin 10 mg | v1, posted March 10, 2026 |
| 2Q25 | $42.765 | −$0.559 | 10 MG | Injection, oritavancin 10 mg | v1, posted March 10, 2026 |
| 1Q25 | $43.324 | +$0.821 | 10 MG | Injection, oritavancin 10 mg | v1, posted December 19, 2025 |
| 4Q24 | $42.503 | +$0.569 | 10 MG | Injection, oritavancin 10 mg | v1, posted June 11, 2025 |
| 3Q24 | $41.934 | +$1.039 | 10 MG | Injection, oritavancin 10 mg | v1, posted June 11, 2025 |
| 2Q24 | $40.895 | −$0.022 | 10 MG | Injection, oritavancin 10 mg | v1, posted March 11, 2025 |
| 1Q24 | $40.917 | +$0.223 | 10 MG | Injection, oritavancin 10 mg | v1, posted December 19, 2024 |
| 4Q23 | $40.694 | −$1.04 | 10 MG | Injection, oritavancin 10 mg | v1, posted October 10, 2024 |
| 3Q23 | $41.734 | −$0.396 | 10 MG | Injection, oritavancin 10 mg | v1, posted June 5, 2024 |
| 2Q23 | $42.13 | +$0.721 | 10 MG | Injection, oritavancin 10 mg | v1, posted February 23, 2024 |
| 1Q23 | $41.409 | −$0.125 | 10 MG | Injection, oritavancin 10 mg | v1, posted December 6, 2023 |
| 4Q22 | $41.534 | −$0.735 | 10 MG | Injection, oritavancin 10 mg | v1, posted June 22, 2023 |
| 3Q22 | $42.269 | −$0.111 | 10 MG | Injection, oritavancin 10 mg | v1, posted June 9, 2023 |
| 2Q22 | $42.38 | – | 10 MG | Injection, oritavancin 10 mg | v1, posted December 14, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.